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Summary Autoradiography with '251-labelled antibodies 17-1-A and 11-285-14 (anti-carcinoembryonic
antigen) injected singly or together into nude mice carrying two distinct human colorectal cancer xenografts
delineates marked changes in distribution and retention of isotope over 72 h, which are relevant to micro-
dosimetry. The antibodies localise independently at low concentrations. Slow accumulation and retention
predominantly in membranes of glands and necrotic areas suggest that therapy will succeed best with isotopes
whose range, half-life and/or mode of delivery can exploit optimally the greater selectivity of the late retention.
Dosimetry in patients with colorectal cancer using '3'I-
radiolabelled antibodies to carcinoembryonic antigen predicts
disappointingly low doses of radiation to tumours before
limiting bone marrow toxicity is approached, but partial
response has been seen, even at an estimated tumour dose of
306 cGy (Begent et al., 1989). Calculations of dose to tumour
based on the assumption of a uniform distribution therein
may well underestimate the cytotoxicity to individual cells
within the mass. It has been suggested that radiolabelled
antibodies to membrane-bound antigens on cells in vitro have
a greater potential for cell kill (Kozak et al., 1986), while
released antigen may adversely affect antibody localisation in
xenografts (Pedley et al., 1989). A comparative study of the
distribution and retention of 17-1-A (Herlyn et al., 1983,
1986) and anti-carcinoembryonic antigen 11-285-14
antibodies (Lewis et al., 1984) over time by autoradiography
in two distinct human colorectal cancer xenografts MAWI
and TAF (Lewis et al., 1983) serves to demonstrate how the
inherent temporal and spatial heterogeneity of isotope
localisation in the tumours might be exploited.
Materials and methods
Mouse monoclonal antibody 17-1-A was kindly provided by
Dr H. Koprowski. Mouse monoclonal antibody 11-285-14
(anti-CEA) was kindly provided by Eli Lilly (Windlesham,
Berks, UK; Dr R. Simmonds), being derived from a hyb-
ridoma originating with Dr C.H.J. Ford.
MAWI and TAF human colonic tumour xenografts were
maintained as subcutaneous xenografts by serial passage in
nude (nu/nu) mice. Details of these models with respect to
histology and CEA production have been published (Lewis et
al., 1983). Briefly, MAWI is a mucoid adenocarcinoma with
signet ring cells, while TAF is a poorly differentiated
adenocarcinoma. Neither secretes detectable levels of CEA.
For autoradiographic studies, nude mice were implanted
subcutaneously with Imm cubes of MAWI and TAF xeno-
graft tissue on opposite flanks. The experiment commenced
after 1 month, using three mice per group, and tumours of a
similar size were employed (approximately 1 g). '25I-labelled
antitumour antibodies (17-1-A and 11-285-14) were
administered via the tail vein either singly (30 j.Ci jg-1) or
as a mixture (15tiCi 5 jLg-' of each antibody) to maintain a
constant protein dose. Tumours were excised at 24, 48 and
72h following administration of the antibody. Resected
xenografts were fixed promptly in 10% buffered formalin for
48 h, processed through graded alcohols, cleared with
inhibisol and impregnated with paraffin wax. Sections were
cut at 5 Atm and collected on gelatin-covered glass slides. The
sections were then dewaxed and covered with Kodak AR 10
autoradiographic stripping film (Kodak, UK) under a safety
light, the inverted film being floated on a bath of distilled
water at 25'C. The slides were left to air dry over silica gel
for 24 h before being placed in exposure boxes at - 20'C for
4 weeks. They were then allowed to reach room temperature
before being developed in freshly filtered Kodak D19
developer (2.5 min) and fixed in Kodafix (I in 10 dilution for
12 min). After air drying overnight, the sections were stained
with Coles' haemotoxylin and aqueous eosin.
Results
MA WI xenograft: localisation of 17-1-A and 11-285-14
antibodies
In the MAWI xenograft, 17-1-A was initially distributed
within fibrovascular cores and along basement membranes of
the tumour. By 72 h the association with blood vessels had
significantly diminished, but there was still accumulation of
grains on the basement membranes in addition to localisation
on cell surfaces and luminal aspects (Figure 1). Likewise the
direct relationship of the 11-285-14 antibody with vascularity
diminished over 72 h, with an increasing number of grains
appearing over isolated tumour cells and on the luminal
surfaces of poorly formed malignant glands, albeit mainly in
peripheral areas of tumour (Figure 2).
Auroradiographs derived from the administration of mixed
antibodies demonstrated the superimposition of 11-285-14
distribution on the pattern of 17-1-A localisation. Luminal
and basement membrane aspects of the malignant glands
were labelled, as were single tumour cells within the
mucinous areas. The overall intensity of grains which, by
comparison with single administration, could be attributed to
17-1-A deposition in the mixture, was diminished in accor-
dance with the reduced amount of antibody given. Both
antibodies appeared to maintain their individual distribution
patterns, with no augmentation of one upon the other
(Figure 3).
TAFxenograft: localisation of 17-1-A and 11-285-14
antibodies
In the TAF xenograft the antibodies also showed changes in
accumulation (seen in grain density and distribution) with
time. At 24 h, the grains associated with 17-1-A antibody
were mainly confined to areas of tumour close to blood
vessels and fibrovascular stroma. By 48 h there was a light
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distribution of grains over tumour cells, but no association
with glandular lumina. A few grains did remain in the blood
vessels. In general the necrotic areas appeared to be less
granular than the viable areas of the tumour. By 72 h there
was heavy accumulation over the tumour cell surfaces,
especially the luminal surfaces of acini. The blood vessels had
cleared, and there was diffuse granularity throughout the
tumour with small foci of heavy staining in areas tending
towards glandular differentiation.
With 11-285-14 the antibody initially concentrated within
or adjacent to blood vessels (Figure 4, 24 h) but was later
found over the tumour cell surfaces and to a reduced extent
in the fibrovascular cores (Figure 5, 72 h). The distribution
was noticeably more focal than the distribution seen in the
MAWI model, giving the impression of antibody molecules
seeping out of the blood vessels, diffusing across the tumour
tissue, being held both at specific binding sites and in cul-de-
sacs of disaggregated or necrotic tissue where mechanical
drainage may be poor.
The mixture of the two antibodies gave a diffuse grain
distribution throughout the tumour with occasional small
focal collections, resembling an additive picture of the two
antibodies given singly.
As a general impression, the overall localisation of both
antibodies was faster in the TAF model than in the MAWI.
This may be attributable to greater vascularity and less nec-
rosis in the former. Within the TAF tumour, the distribution
of 11-285-14 antibody seemed slower than that of the 17-1-A.
Whether this was due to impedance by a small quantity of
released carcinoembryonic antigen remains speculative, but
the focal retention of thel 1-285-14 corresponded with local
concentrations of CEA in acini, demonstrated by immunohis-
tochemistry. However, when immunoperoxidase (indirect
staining) was used to demonstrate CEA in sections from
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Figure I Autoradiograph showing localisation of 17-1-A
antibody in the MAWI xenograft 72 h after administration. Note
the accumulation of grains along the membranes of poorly
formed malignant glands. H & E counterstain ( x 100).
Figure 2 Autoradiograph showing localisation of anti-CEA
antibody (11-285-14) in the MAWI xenograft 72 h after administ-
ration. Note the intense labelling of individual tumour cells and
accumulation of grains in the extracellular mucin. The surfaces of
the malignant glands are only weakly labelled. H & E counter-
stain ( x 100).
MAWI xenografts which had received 11-285-14 antibodies
72 h previously, only a few of the areas of weak focal reac-
tivity were associated with significant accumulation of grains.
Discussion
Two human colorectal cancer xenografts, with similar gross
accumulation of '251I-labelled anti-CEA and 17-1-A antibodies
over 72 h (data after Pressman et al., 1957, not shown) and
with similar expression of CEA (TAF 1.5-6.2fig g-'; MAWI
34-59 gg-'; Lewis et al., 1983), show uneven distribution
of antibodies over time. While this might have been expected
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Figure 3 Autoradiograph showing localisation of 17-1-A/11-285-
14 mixture in the MAWI xenograft 72 h after administration.
Note the combined pattern of localisation, with labelling of
individual tumour cells, extracellular mucin, and association of
grains with membranes of malignant glands H & E counterstain
(x 100).
Figure 4 Autoradiography showing localisation of 11-285-14 in
fibrovascular stroma in the TAF xenograft, 24 h after administra-
tion. H & E counterstain (x 100).
Figure 5 Autoradiograph showing localisation of 11-285-14 in
the TAF xenograft 72 h after administration, with focal labelling
of the tumour acini and grains over tumour cells. Note there are
fewer grains associated with the blood vessels. H & E counter-
stain ( x 100).220 R.B. PEDLEY et al.
for the moderately differentiated MAWI tumour, the TAF
tumour, with apparently more consistent undifferentiated
morphology, shows isolated foci of retention. The antibodies
take a significant time, in relation to the half-life of '3'I, to
traverse the tumours after extravasation from the blood and
their ultimate retention is probably as much determined by
physiological factors as by distribution of antigen. Superim-
posed on the antibody passage through tumour tissue in
accordance with Stokes' Law, antigen-targeted antibodies
depart from the classical diffusion and convection transport
equations as they are held back, producing spatial and tem-
poral heterogeneities which will have severe implications on
the survival prognosis of individual cells. The simple linear
quadratic equation between cell survival and tumour dose is
not expected to hold true in radioimmunotherapy.
Well-oxygenated cells neighbouring the bloodstream will
initially receive the full impact from circulating radiolabelled
antibodies as well as any specific dose enhancement due to
retention. This is clearly demonstrated by the 24h
autoradiographs in either model. Late retention occurs
markedly in necrotic areas and is best exploited for therapy
by isotopes with sufficient range to sterilise dispersed cells
within these spaces as well as surrounding viable tumour
cells.
Evidence is accumulating that an assessment of tumour
sterilisation on a single absorbed dose value for the whole
tumour may possess serious shortcomings. Sizeable fluctua-
tions (at least by a factor of 4) in the local dose have been
shown by implanting micro-thermoluminescent dosimeters in
tumours (Griffith et al., 1988). In vitro survival curves with
212 Bi-labelled membrane specific and non-specific antibodies
have demonstrated marked high efficiencies in cell killing due
to antibody binding (Kozak et al., 1986). Calculations of the
energy deposited in the cell nuclei resulting from antibody
binding have shown significant departures from the mean
energy deposition resulting from a uniform distribution of
the label, an implicit assumption of the conventional MIRD
procedure. For example, the ratio of the mean dose per
tumour cell nucleus from '311-labelled antibodies bound to
cell surface antigen versus a uniform distribution of the
antibody, for a cell separation of 40 tm, can be greater than
2. The magnitude of the dose enhancement is strongly depen-
dent on the radionuclide emission range, the tumour his-
tology and the uniformity of antibody binding. For colonic
tumours of the TAF type where antibody localises so focally,
short range emissions must be ineffective for therapy. For an
improved appraisal of the efficacy of radioimmunotherapy, it
is essential that more detailed studies relating antibody reten-
tion to the prevalence of stem cells in three-dimensional
architecture in tumours should be performed.
Calculations from direct antibody deposition of activity
should not deter exploration of systems which incorporate a
time delay. For, example, one could attempt to generate a
short-lived radioisotope in situ from a less destructive isotope
targeted to the tumour, such as a soft beta parent generating
a hard beta or alpha particle emitting daughter in situ.
Gansow (personal communication) has already suggested the
212Pb-2_2Bi alpha generator system. If, as suggested by our
results, the major location of the antibodies is close to the
blood vessels at 24 h, the peak activity in this system (2.8 h)
occurs too early to be readily exploited for therapy. It is
doubtful whether even Fab' fragments would disseminate
sufficiently quickly into the centre of the tumours. Alterna-
tively, one could design a two-phase system in which a bound
antitumour-antihapten antibody, having had time to
traverse the tumour and clear the bloodstream, will capture a
readily diffusible labelled hapten, sent in sequentially, 72 h
after antibody administration. Simple chelating agents may
clear too rapidly to be trapped, and molecular size and
charge would have to be optimised. Since the bulk of the
hapten would clear more rapidly than an intact antibody, it
might be possible to consider radioactive isotopes which have
been discounted previously on the grounds of their predicted
toxicities when directly attached to antibodies.
Where heterogeneity of antigen expression presents severe
restrictions to the progress of radioimmunotherapy, the
results of this study provide the basis for some optimism that
these problems can in part be overcome by the administra-
tion of cocktails of monoclonal antibodies directed against
multiple non-overlapping antigens. The regimen devised
should incorporate mixtures of carrier and isotope such that
all positions and times of retention are best matched to
destroy cells which would otherwise be capable of being
recruited into division after the preliminary response has
depleted their neighbours.
The authors would like to thank Mr R. Barnett for his expertise in
preparing the photomicrographs, and to express their gratitude to
the Cancer Research Campaign for financial support.
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